Trident Lifeline share price & results
- Sept 2026
- Oct 2026
Surat-based hybrid pharmaceutical formulations maker exporting tablets, capsules and other dosage forms under own brands and via contract/loan-license manufacturing to Africa, Latin America, CIS and East Asia.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 32.7 | −29.2% YoY | Quarterly, as filed | Quarter to Sept 2026 | Revenue from operations as filed. |
| Operating margin | 29.8 | +5.3 pts YoY | Operating profit / revenue | Quarter to Sept 2026 | For the quarter; a change is in percentage points. |
| Net profit | 6.6 | −21.9% YoY | Quarterly, as filed | Quarter to Sept 2026 | Profit after tax as filed. |
| Return on equity | 19.88 | +4.4 pts | Trailing twelve months | TTM to Sept 2026 | Adjusted profit attributable to owners ÷ average owners’ equity. |
| Free cash flow margin | -22.03 | −4.7 pts | Fiscal year | FY ending Mar 2026 | (Operating cash flow − fixed-asset purchases + disposals) ÷ revenue. |
| Revenue growth (YoY) | 55.23 | −45.1 pts | Trailing twelve months | TTM to Sept 2026 | Revenue change against the same period one year earlier. |
Price
Performance +45.2% 1Y
1Y: ₹300 on 24 Oct 2025 → ₹435.5. High ₹435.5 (27 Oct 2026), low ₹237.9 (17 Mar 2026).
- Previous close
- ₹418.95
- Market cap
- ₹302 Cr
- 52-week range
- ₹237.9 – ₹435.5
- One year
- +46.14%
- Price to earnings (TTM to Sept 2026)
- 13.33×
- Return on equity (TTM to Sept 2026)
- 19.88%
Overview
- Symbol
- NSE:TLL
- Sector
- Healthcare
- Exchange
- NSE
- Currency
- INR
What Trident Lifeline Limited does
Based on the company's own presentations, annual report and earnings calls.
Trident Lifeline manufactures pharmaceutical formulations (tablets, capsules, liquids, ointments, injectables, gels, syrups and more) under its own brands and facilities, and also operates through loan-license and contract manufacturing arrangements with third parties. It sells domestically and exports directly under its own brands across registered markets, while also engaging in bulk/merchant exports to B2B players and distributors. Through subsidiaries and stake acquisitions it has extended into herbal/wellness products, skin & hair cosmetics, specialty-chemical intermediates, injectables and medical devices, controlling procurement, manufacturing, exports and sales & marketing across the value chain.
Segments
- Own-brand pharmaceutical formulations
- Contract / loan-license manufacturing
- Merchant / bulk exports
- Herbal & wellness products
- Skin & hair cosmetics
- Specialty-chemical intermediates
- Injectables
- Medical devices
- Manufacturing sites
- 5 (own plant + TNS Pharma, TLL Industries, TLL Parenterals (under construction) and Trident Mediquip)
- Consolidated manufacturing capacity per month
- Tablets 120 mn; Capsules 120 mn; Injectables 10 mn; Liquid bottles 3 mn; Dry powder bottles 3 mn; Ointments 3 mn
- Products in portfolio
- 3,625 (as of Mar 31, 2026)
- Countries present globally
- 46
- Countries where products already registered
- 23
- Export product registration applications
- 1,091 registered + 2,534 in process = 3,625 total (as of Mar 31, 2026)
Fundamentals
Ratios, each with its period
Current values with the period they cover; the trend reads across the 5 fiscal years held (Mar 2022 to Mar 2026).
Financials
What the filings say
Net profit, year on year: −22% (quarter to sept 2026 against sept 2025).
| Line item | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 21 | 19 | 46 | 24 | 32 | 27 | 33 |
| Expenses | 12 | 15 | 14 | 35 | 17 | 25 | 20 | 23 |
| Operating profit | 4 | 6 | 5 | 11 | 6 | 7 | 7 | 10 |
| Operating margin | 25.1% | 26.8% | 26.2% | 24.4% | 26.6% | 21.1% | 26.9% | 29.8% |
| Other income | 1 | 2 | 1 | 2 | 1 | 2 | 1 | 1 |
| Interest | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 1 |
| Depreciation | 0 | 1 | 1 | 1 | 1 | 0 | 1 | 1 |
| Profit before tax | 4 | 6 | 5 | 11 | 6 | 8 | 7 | 9 |
| Tax rate | 23.3% | 27.6% | 24.8% | 24.2% | 32.2% | 28.8% | 23.5% | 25.1% |
| Net profit | 3 | 4 | 3 | 8 | 4 | 6 | 5 | 7 |
| EPS (₹ per share) | 2.63 | 3.78 | 3.03 | 7.26 | 3.36 | 4.74 | 4.21 | 5.50 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Sales | 38 | 45 | 68 | 121 |
| Expenses | 31 | 36 | 50 | 91 |
| Operating profit | 7 | 8 | 18 | 29 |
| Other income | 1 | 2 | 3 | 5 |
| Interest | 0 | 1 | 1 | 2 |
| Depreciation | 0 | 1 | 2 | 2 |
| Profit before tax | 7 | 9 | 19 | 30 |
| Net profit | 7 | 7 | 14 | 22 |
| Line item | Mar 2023 | Mar 2024 | Mar 2025 | Sept 2025 | Mar 2026 | Sept 2026 |
|---|---|---|---|---|---|---|
| Equity capital | 12 | 12 | 12 | 12 | 12 | 12 |
| Reserves | 34 | 41 | 54 | 69 | 87 | 99 |
| Borrowings | 3 | 6 | 15 | 59 | 25 | 42 |
| Other liabilities | 7 | 14 | 17 | 47 | 36 | 21 |
| Total liabilities | 56 | 73 | 98 | 187 | 159 | 175 |
| Fixed assets | 3 | 8 | 15 | 46 | 29 | 30 |
| Capital work in progress | 0 | 4 | 1 | 2 | 0 | 1 |
| Investments | 4 | 4 | 12 | 9 | 20 | 28 |
| Other assets | 49 | 57 | 70 | 130 | 111 | 116 |
| Total assets | 56 | 73 | 98 | 187 | 159 | 175 |
| Line item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operations | 0 | -17 | 1 | 2 | 8 |
| Cash from investing | 0 | -6 | -11 | -8 | -20 |
| Cash from financing | 1 | 36 | 2 | 2 | 14 |
| Net cash flow | 0 | 14 | -8 | -4 | 2 |
| Free cash flow | -1 | -19 | -8 | -3 | -7 |
| Line item | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Debtor days | 24 | 83 | 140 | 112 | 110 | 177 |
| Inventory days | 349 | 95 | 129 | 137 | 167 | 136 |
| Days payable | 266 | 134 | 87 | 94 | 97 | 153 |
| Cash conversion cycle | 107 | 44 | 183 | 155 | 180 | 160 |
| Working capital days | 12 | 49 | 274 | 246 | 226 | 192 |
| Return on capital employed | 34.0% | 55.0% | 25.0% | 19.0% | 28.0% | 26.0% |
| Dividend payout | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
What the price assumes
AttractiveTo justify its price of ₹436, this stock must grow earnings at 18% every year for 7 years. Our analysis caps realistic growth at ~42%. At that growth it is worth ₹1409 — upside of 224%.
- Growth the price implies
- 18.4% a year
- for 7 years, fading to 4%
- It has actually compounded at
- 42.4% a year
- net profit, FY23–FY26
- The gap
- -0.2 pp
- 224% downside if it only repeats history
Ownership
Who owns it
Promoters hold 62.53% as of Oct 2026; institutions added 0.00 pts since Sept 2026.
- Promoters 62.53%
- Foreign institutions 1.16%
- Domestic institutions 0.22%
- Public 36.11%
Who bought this quarter
since Sep 2026
Disclosed holders that added to a position or appeared on the register for the first time, biggest addition first.
- newly disclosed 0.20% held
The same filing shows 1 holder trimming and 0 off the list — both are in the register beside this.
Who is on the register
Named in the Oct 2026 filing
Every holder of Trident Lifeline Limited above SEBI's 1% disclosure line, and what changed since Sep 2026.
| Holder | Stake | Change |
|---|---|---|
| 23.02% | −0.05 pp | |
| 7.16% | unchanged | |
| 7.00% | unchanged | |
| 5.60% | unchanged | |
| 5.17% | unchanged | |
| 3.96% | unchanged | |
| 3.96% | unchanged | |
| 3.33% | unchanged | |
| 3.01% | unchanged | |
| 0.91% | unchanged | |
| 0.85% | unchanged | |
| 0.83% | unchanged |
A holder disappearing from this list has fallen below the 1% line — it is not necessarily a sale. Percentages are of total shares, as disclosed in the company's own filing. Who was buying across the market this quarter.
Your own record
Start an Inve Case for Trident Lifeline Limited
Free account: one company. Everything above stays public.
Write why you follow Trident Lifeline Limited and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading
Other Healthcare companies
- AS
ASARFIASARFI HOSPITAL LIMITED - ME
MEDICAMEQMedicamen Biotech Limited - QM
QMSMEDIQMS Medical Allied Services Limited - AA
AAREYDRUGSAarey Drugs & Pharmaceuticals Limited - NU
NURECANureca Limited - LY
LYKALABSLyka Labs - ZE
ZENOTECHZenotech Laboratories Limited - AM
AMBALALSAAmbalal Sarabhai Enterprises Limited
Learn to analyse Trident Lifeline Limited
Guides on how to read this kind of business and the numbers that matter.